| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 1.485.900 $ | +33.097 $ | +4,2 % | 3 | 1.452.803 $ | -1.657.083 $ | -52,3 % | 3 | 3.109.886 $ | +956.951 $ | +46,9 % | 3 | ||||
| Werewolf Therapeutics, Inc. | HOWL | → 0 | Schwach | 490.486 $ | +117.290 $ | +31,4 % | 1 | 373.196 $ | -787.335 $ | -67,8 % | 1 | 1.160.531 $ | +518.410 $ | +80,7 % | 1 |
| TScan Therapeutics, Inc. | TCRX | → 0 | Neutral | 630.000 $ | +0 $ | +0,0 % | 1 | 630.000 $ | -516.600 $ | -45,1 % | 1 | 1.146.600 $ | +233.100 $ | +25,5 % | 1 |
| Barinthus Biotherapeutics plc. | BRNS | → 0 | 365.414 $ | -84.193 $ | -18,7 % | 1 | 449.607 $ | -353.148 $ | -44,0 % | 1 | 802.755 $ | +205.441 $ | +34,4 % | 1 | |
| 1.485.900 $ | +33.097 $ | +4,2 % | 3 | 1.452.803 $ | -1.657.083 $ | -52,3 % | 3 | 3.109.886 $ | +956.951 $ | +46,9 % | 3 | ||||